The majority of breast cancers are hormone receptor positive (HR positive), including estrogen receptor (ER) and/or progesterone receptor (PR) positive, with endocrine therapy (ET) remaining the backbone of therapy (2–4). This evidence concerns the gene NR4A1 and breast carcinoma.